ALK and non-small cell lung carcinoma: Soria et al. [19] performed a pooled meta- analysis of three large prospective crizotinib clinical trials for ALK positive NSCLC, designated as PROFILE 1005 [29], PROFILE 1007 [30] and PROFILE 1014 [31,32], to evaluate the relationship between the percentage of ALK rearrangement positive cells and clinical outcomes or crizotinib responses.